Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 7705

1.

Biomarkers, Assays, and Therapies for Alzheimer Disease.

Beriault DR, Diamandis EP, Portelius E, Perret-Liaudet A, Salloway S.

Clin Chem. 2015 May 26. pii: clinchem.2015.241901. [Epub ahead of print] No abstract available.

PMID:
26015517
2.

CSF tau correlates with CJD disease severity and cognitive decline.

Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Nitsan Z, Appel S, Kahana E, Rosenmann H.

Acta Neurol Scand. 2015 May 25. doi: 10.1111/ane.12441. [Epub ahead of print]

PMID:
26014384
3.

The relationship between atrophy and hypometabolism: is it regionally dependent in dementias?

Rodriguez-Oroz MC, Gago B, Clavero P, Delgado-Alvarado M, Garcia-Garcia D, Jimenez-Urbieta H.

Curr Neurol Neurosci Rep. 2015 Jul;15(7):562. doi: 10.1007/s11910-015-0562-0.

PMID:
26008810
4.

[American Academy of Neurology, Washington, 18-25 April 2015].

Sibon I, de Toffol B, Azulay JP, Sellal F, Thomas-Antérion C, Léger JM, Pierrot-Deseilligny C.

Rev Neurol (Paris). 2015 May 21. pii: S0035-3787(15)00748-1. doi: 10.1016/j.neurol.2015.04.005. [Epub ahead of print] Review. French.

PMID:
26005122
5.

The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.

Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E, Ertan S, Atasoy İL, Alaylıoğlu M, Araz ÖS, Önal B, Gündüz A, Apaydın H, Kızıltan G, Ulutin T, Gürvit H, Yılmazer S.

J Neuroimmunol. 2015 Jun 15;283:50-7. doi: 10.1016/j.jneuroim.2015.04.014. Epub 2015 Apr 25.

PMID:
26004156
6.

Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.

Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, Thambisetty M, Prince JL, Zhou Y, Soldan A, Wong DF, O'Brien RJ, Ferrucci L, Albert MS.

Neurobiol Aging. 2015 Apr 4. pii: S0197-4580(15)00202-X. doi: 10.1016/j.neurobiolaging.2015.04.001. [Epub ahead of print]

PMID:
26004017
7.

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.

Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Ann Clin Transl Neurol. 2015 May;2(5):534-47. doi: 10.1002/acn3.192. Epub 2015 Mar 21.

8.

Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain.

Richards D, Sabbagh MN.

Neurol Ther. 2014 Nov 27;3(2):79-88. doi: 10.1007/s40120-014-0022-9. eCollection 2014 Dec. Review.

9.

Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications.

De Toro J, Herschlik L, Waldner C, Mongini C.

Front Immunol. 2015 May 4;6:203. doi: 10.3389/fimmu.2015.00203. eCollection 2015. Review.

10.

Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia.

Rostgaard N, Waldemar G, Nielsen JE, Simonsen AH.

Dement Geriatr Cogn Disord. 2015 May 13;40(1-2):54-62. [Epub ahead of print]

PMID:
25998699
11.

The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research.

Kansal K, Irwin DJ.

Psychiatr Clin North Am. 2015 Jun;38(2):309-322. doi: 10.1016/j.psc.2015.02.002. Epub 2015 Mar 18. Review.

PMID:
25998118
12.

The Neuropsychiatric Examination of the Young-Onset Dementias.

Ducharme S, Dickerson BC.

Psychiatr Clin North Am. 2015 Jun;38(2):249-264. doi: 10.1016/j.psc.2015.01.002. Epub 2015 Mar 12. Review.

PMID:
25998114
13.
14.

MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.

Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S, Jahn H.

PLoS One. 2015 May 20;10(5):e0126423. doi: 10.1371/journal.pone.0126423. eCollection 2015.

15.

Body fluid biomarkers in Alzheimer's disease.

Lu H, Zhu XC, Jiang T, Yu JT, Tan L.

Ann Transl Med. 2015 Apr;3(5):70. doi: 10.3978/j.issn.2305-5839.2015.02.13. Review.

16.

Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Ossenkoppele R, Mattsson N, Teunissen CE, Barkhof F, Pijnenburg Y, Scheltens P, van der Flier WM, Rabinovici GD.

Neurobiol Aging. 2015 Apr 25. pii: S0197-4580(15)00231-6. doi: 10.1016/j.neurobiolaging.2015.04.011. [Epub ahead of print]

PMID:
25990306
17.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H.

JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.

PMID:
25988462
18.

Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models.

Maia LF, Kaeser SA, Reichwald J, Lambert M, Obermüller U, Schelle J, Odenthal J, Martus P, Staufenbiel M, Jucker M.

EMBO Mol Med. 2015 May 15. pii: e201505026. doi: 10.15252/emmm.201505026. [Epub ahead of print]

19.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 May 2. pii: S1353-8020(15)00193-5. doi: 10.1016/j.parkreldis.2015.04.027. [Epub ahead of print]

PMID:
25971633
20.

Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.

Otsubo Y.

Clin Ther. 2015 May 8. pii: S0149-2918(15)00243-X. doi: 10.1016/j.clinthera.2015.04.010. [Epub ahead of print]

PMID:
25963998
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk